M&A Deal Summary

Jazz Pharmaceuticals Acquires Orphan Medical

On April 19, 2005, Jazz Pharmaceuticals acquired life science company Orphan Medical from Alta Partners for 123M USD

Acquisition Highlights
  • This is Jazz Pharmaceuticals’ 1st transaction in the Life Science sector.
  • This is Jazz Pharmaceuticals’ 6th largest (disclosed) transaction.
  • This is Jazz Pharmaceuticals’ 1st transaction in the United States.
  • This is Jazz Pharmaceuticals’ 1st transaction in Minnesota.

M&A Deal Summary
Date 2005-04-19
Target Orphan Medical
Sector Life Science
Buyer(s) Jazz Pharmaceuticals
Sellers(s) Alta Partners
Deal Type Add-on Acquisition
Deal Value 123M USD

Target

Orphan Medical

Minnetonka, Minnesota, United States
Orphan Medical is a specialty pharmaceutical company which acquires, develops, and markets pharmaceuticals for inadequately treated and uncommon diseases, including sleep disorders. The Company recently received regulatory approval in the United States for Xyrem, a therapeutic for the treatment of cataplexy. Orphan Medical was a public company traded on Nasdaq under the symbol ORPH.

Search 193,092 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Jazz Pharmaceuticals

Dublin 4, Ireland

website

Category Company
Founded 2003
Sector Life Science
Employees1,940
Revenue 2.4B USD (2020)
DESCRIPTION
Jazz Pharmaceuticals office in Palo Alto, California.
Jazz Pharmaceuticals office in Palo Alto, California.

Jazz Pharmaceuticals is a specialty biopharmaceutical company that identifies, develops and commercializes products to address unmet medical needs in focused therapeutic areas. Jazz Pharmaceuticals was founded in 2003 and is based in Dublin, Ireland.

DEAL STATS #
Overall 1 of 6
Sector (Life Science) 1 of 6
Type (Add-on Acquisition) 1 of 6
State (Minnesota) 1 of 1
Country (United States) 1 of 4
Year (2005) 1 of 1
Size (of disclosed) 6 of 6
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2012-04-30 EUSA Pharma

Langhorne, Pennsylvania, United States

EUSA Pharma is a trans-Atlantic specialty pharmaceutical company focused on oncology and critical care. EUSA intends to build a portfolio of products that are on the market or in late-stage clinical trials through acquisitions and in-licensing. The company has a sales and marketing organization and commercial infrastructure in the US and all major European countries.

Buy $680M

Seller(S) 1

SELLER

Alta Partners

Jackson, Wyoming, United States

Investor Investor Investor Investor

website

Category Venture Capital Firm
Founded 1996
PE ASSETS 2.6B USD
Size Large
Type Sector Focused
DESCRIPTION

Alta Partners is a venture capital firm that targets investments in early and later stage life science companies, including biopharmaceuticals, medical technology, and information technology businesses. Alta was formed as an early stage investor but has since expanded its investment range to provide later stage growth capital to private and young public companies. Alta was established in 1996 and is headquartered in San Francisco, California.

DEAL STATS #
Overall 22 of 84
Sector (Life Science) 13 of 64
Type (Add-on Acquisition) 14 of 45
State (Minnesota) 3 of 4
Country (United States) 20 of 74
Year (2005) 3 of 6
Size (of disclosed) 19 of 23
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2005-01-20 Angiosyn

La Jolla, California, United States

Angiosyn, Inc. is a biopharmaceutical company developing novel proprietary biologics for controlling angiogenesis. The company's initial therapeutic indication is for ophthalmic diseases, such as macular degeneration and diabetic retinopathy, which due to angiogenesis can lead to decreased vision and blindness.

Sell $527M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2005-05-17 Veloxis Pharmaceuticals

Cary, North Carolina, United States

Veloxis Pharmaceuticals is a fully integrated specialty pharmaceutical company that develops a clinically validated drug-delivery platform for overcoming the deficiencies of drugs with low water solubility, thus improving the bioavailability of marketed drugs and new chemical entities (NCEs). Veloxis Pharmaceuticals is based in Cary, North Carolina.

Buy €15M
Mergr

Product

Company

Legal